Navigation Links
Study reveals how cancer drug causes diabetic-like state
Date:4/3/2012

Scientists at Dana-Farber Cancer Institute have discovered why diabetic-like symptoms develop in some patients given rapamycin, an immune-suppressant drug that also has shown anti-cancer activity and may even slow ageing.

Rapamycin is widely used to prevent organ rejection and is being tested as a cancer treatment in clinical trials.

About 15 percent of patients, however, develop insulin resistance and glucose intolerance after taking the drug; until now, scientists had not identified the reason.

In a study published in Cell Metabolism, the researchers report that normal mice given rapamycin were more likely to have trouble regulating their blood sugar because of a drop in insulin signaling, which in turn was triggered by activity of a protein called Yin Yang 1, or YY1. But animals in which the YY1 protein was "knocked out" in their muscles had no such response to rapamycin they were protected against the development of diabetes-like symptoms. This result pinpointed YY1 as the target of rapamycin responsible for the loss of normal insulin function.

One of the finding's implications is that physicians should consider giving anti-diabetes drugs along with rapamycin, says Pere Puigserver, PhD, senior author of the report.

The results also raise a caution flag for researchers and non-scientists who are excited about the potential for rapamycin to extend life, based on recent studies in animals including mammals, he notes.

"The possibility of increased diabetes risk needs to be taken into account" in further research on the anti-ageing properties of rapamycin and related compounds, says Puigserver.

Rapamycin is a drug derived from bacteria found on Easter Island, and was approved in 1999 by the FDA as an immunosuppressant in transplant patients.

One of its actions is to inhibit the important mTOR signaling pathway in cells (mTOR stands for "mammalian target of rapamycin"). The mTOR pathway is a critical factor in regulating the growth, proliferation, survival and motility of cells; elevated mTOR activity is a hallmark of many cancers.

In clinical trials rapamycin and a related drug are being evaluated in kidney cancer, brain tumors, and mantle cell lymphoma, among others. Intriguingly, rapamycin has been found in some experiments to extend healthy lifespan in yeast, flies and mammals, and delays age-related diseases, including cancer and atherosclerosis. But the raised risk of deleterious pre-diabetes symptoms has been a concern and something of a mystery. In 2007, Puigserver and colleagues reported in Nature that mTOR causes an increase in mitochondria the cell's power plants in skeletal muscles; suppressing mTOR activity with rapamycin led to a diabetic state. That research also revealed that among the proteins "downstream" of mTOR in the signaling pathway is Yin Yang 1 (YY1), a transcription factor a protein that controls the expression of genes.

"We thought that maybe YY1 was responsible for the diabetic effects," says Puigserver. An increase in YY1 activity caused by rapamycin could suppress the production of insulin and related hormones which are necessary for muscles to take up glucose (sugar) for energy and keep blood sugar levels stable.

To test that idea, they bred mice that lacked the YYI gene and protein in their skeletal muscles. When these mice were given rapamycin, it didn't affect their muscles' glucose uptake or insulin signaling in effect, they were immune to the diabetic effects of rapamycin.

The investigators are continuing their studies: one goal is to discover why only a minority of human patients develop diabetes-like conditions with rapamycin treatment. One possibility that the risk is modulated by dietary factors, Puigserver says.


'/>"/>

Contact: Anne Doerr
anne_doerr@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert  

Related medicine news :

1. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
2. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
3. TV drama can be more persuasive than news program, study finds
4. Study carried out into biological risks of eating reptiles
5. Neuroimaging study may pave way for effective Alzheimers treatments
6. Study finds racial gaps continue in heart disease awareness
7. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
8. First blinded study of venous insufficiency prevalence in MS shows promising results
9. Soothing infants with food focus of childhood obesity study
10. People with anxiety disorder less able to regulate response to negative emotions, study shows
11. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study reveals how cancer drug causes diabetic-like state
(Date:3/27/2017)... ... March 27, 2017 , ... From 1999 to ... responsible for over 33,000 of the 52,404 drug-related deaths in 2015.(2) To combat ... which proposes a tax on prescription opioids to fund drug rehabilitation and prevention ...
(Date:3/25/2017)... ... 2017 , ... Norland at Swissray is pleased to announce the release of the ... ELITE DXA has an active scan window, which is more than double that of existing ... scan area could not undergo an accurate total body bone density or body composition study. ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... Digital Scientists, ... excited to announce the opening of a Greenville, South Carolina location. The ... digital progress in Greenville. , “We’ve been working with South Carolina clients for years ...
(Date:3/24/2017)... ... March 24, 2017 , ... Mlynarek ... services to families and business owners across eastern Michigan, is connecting with the ... struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works to ensure ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She will ... The majority of cases litigated under ERISA involve claims for long-term disability benefits. ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)...   The Accreditation Council for Medical Affairs ... the pharmaceutical industry has appointed Dr. Jane ... formed scientific advisory board. Dr. Chin will be ... ever medical affairs think tank within the pharmaceutical ... ACMA, please visit  www.medicalaffairsspecialist.org .  Connect with ...
(Date:3/24/2017)... NEW YORK , March 24, 2017 ... ... Research, a leading publisher of cannabis market research, the legal ... 27 percent CAGR through 2021, despite conflicting signals from the ... Analytics, points out that the two biggest drivers of growth ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... offering. ... is very strong with a total of 97 drug candidates. Pharma giant ... are involved in the development of the IPF therapeutics. The IPF pipeline ... stage, 15 are in Phase II stage, 12 are in Phase I ...
Breaking Medicine Technology: